Peter Attia MDPeter evaluates longevity drugs, aspirin for CVD, & strategies to improve muscle (AMA 76 sneak peek)
Episode Details
EPISODE INFO
- Released
- October 27, 2025
- Duration
- 14m
- Channel
- Peter Attia MD
- Watch on YouTube
- ▶ Open ↗
EPISODE DESCRIPTION
In this “Ask Me Anything” (AMA) episode, Peter revisits the “proven, promising, fuzzy, noise, nonsense” scale and applies it to a variety of popular topics. He begins with a refresher on what each category represents before classifying a range of interventions based on the strength of their supporting evidence. The conversation spans three main areas: drugs for geroprotection (including GLP-1 receptor agonists, SGLT2 inhibitors, methylene blue, and telomere-lengthening supplements), the use of low-dose aspirin for cardiovascular disease prevention, and strategies to improve muscle mass through optimal protein intake and follistatin gene therapy. This episode provides a clear, evidence-based overview for listeners seeking to understand where these popular health and longevity interventions stand on the spectrum of scientific credibility. View show notes here: https://bit.ly/47o4f0a Become a member to receive exclusive content: https://peterattiamd.com/subscribe/ Sign up to receive Peter's email newsletter: https://peterattiamd.com/newsletter/ We discuss: 00:09 - A scale for evaluating scientific claims: proven, promising, fuzzy, noise, or nonsense 06:29 - Strong convictions, loosely held: the mindset that separates great scientists from the rest 12:27 - GLP-1 receptor agonists: are there benefits beyond improving metabolic health and promoting weight loss? In the full episode, we also discuss: -GLP-1 drugs and the brain: exploring the potential cognitive benefits -GLP-1 drugs and lifespan: examining the evidence for potential geroprotective effects -Rapamycin and geroprotection: why it remains in the “promising” category -SGLT2 inhibitors and their potential geroprotective effect -Methylene blue: examining the evidence of an anti-aging effect -Methylene blue’s potential neuroprotective effects: limited and inconsistent evidence in humans, and the challenges of dosing and safety -Telomeres: what they are, how they relate to aging, and why telomere-lengthening supplements lack credible scientific evidence -Does the idea of targeting telomere length to extend lifespan have scientific merit? -Low-dose aspirin for cardiovascular disease prevention: weighing its clot-prevention benefits against bleeding risks across different populations -Rethinking the protein RDA: why most people need twice the recommended amount for muscle health -Debunking the protein–cancer myth: why higher protein intake doesn’t promote tumor growth -The biology of follistatin and myostatin, and why follistatin gene therapy has become an emerging topic of interest for muscle growth -Follistatin gene therapy for muscle growth: state of the evidence in animals and humans, and the technical challenges and regulatory barriers -Why injectable follistatin is theoretically possible but impractical for real-world use -More. -------- About: The Peter Attia Drive is a deep-dive podcast focusing on maximizing longevity, and all that goes into that from physical to cognitive to emotional health. With over 90 million episodes downloaded, it features topics including exercise, nutritional biochemistry, cardiovascular disease, Alzheimer’s disease, cancer, mental health, and much more. Peter Attia is the founder of Early Medical, a medical practice that applies the principles of Medicine 3.0 to patients with the goal of lengthening their lifespan and simultaneously improving their healthspan. Learn more: https://peterattiamd.com Connect with Peter on: Facebook: http://bit.ly/PeterAttiaMDFB Twitter: http://bit.ly/PeterAttiaMDTW Instagram: http://bit.ly/PeterAttiaMDIG Subscribe to The Drive: Apple Podcast: http://bit.ly/TheDriveApplePodcasts Overcast: http://bit.ly/TheDriveOvercast Spotify: http://bit.ly/TheDriveSpotify Google Podcasts: http://bit.ly/TheDriveGoogle Disclaimer: This podcast is for general informational purposes only and does not constitute the practice of medicine, nursing, or other professional healthcare services, including the giving of medical advice. No doctor-patient relationship is formed. The use of this information and the materials linked to this podcast is at the user's own risk. The content on this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Users should not disregard or delay in obtaining medical advice for any medical condition they have, and they should seek the assistance of their healthcare professionals for any such conditions. I take conflicts of interest very seriously. For all of my disclosures and the companies I invest in or advise, please visit my website where I keep an up-to-date and active list of such companies. For a full list of our registered and unregistered trademarks, trade names, and service marks, please review our Terms of Use: https://peterattiamd.com/terms-of-use/
SPEAKERS
Peter Attia
hostPhysician and host of The Drive podcast, focused on longevity and performance medicine.
EPISODE SUMMARY
In this episode of Peter Attia MD, featuring Peter Attia and Peter Attia, Peter evaluates longevity drugs, aspirin for CVD, & strategies to improve muscle (AMA 76 sneak peek) explores attia’s evidence scale for longevity claims and GLP‑1 questions Peter Attia introduces a five-category scale—proven, promising, fuzzy, noise, nonsense—to evaluate the strength of scientific and medical claims in biology.
RELATED EPISODES
